
News • EGFR-mutated non-small cell lung cancer
NSCLC: Surgical combination therapy may prolong disease control
In metastatic EGFR-mutated non-small cell lung cancer (NSCLC), targeting residual disease through surgery can extend the benefits of EGFR TKI therapy beyond standard monotherapy, a new study finds.